Oryzon Genomics S.A. (ORYZF)
OTCMKTS
· Delayed Price · Currency is USD
3.223
0.00 (0.00%)
At close: Jun 9, 2025
Oryzon Genomics Revenue
Oryzon Genomics had revenue of $7.95M in the twelve months ending March 31, 2025, down -48.05% year-over-year. In the year 2024, Oryzon Genomics had annual revenue of $7.62M, down -51.43%.
Revenue (ttm)
7.95M
Revenue Growth
-48.05%
P/S Ratio
31.52
Revenue / Employee
169.23K
Employees
47
Market Cap
250.70M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.62M | -8.07M | -51.43% |
Dec 31, 2023 | 15.69M | -1.09M | -6.50% |
Dec 31, 2022 | 16.78M | 4.70M | 38.97% |
Dec 31, 2021 | 12.07M | 425.74K | 3.66% |
Dec 31, 2020 | 11.65M | 112.98K | 0.98% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Oryzon Genomics News
- 4 weeks ago - ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project) - GlobeNewsWire
- 7 weeks ago - ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat - GlobeNewsWire
- 3 months ago - ORYZON to Provide Corporate Progress Updates at Several Events in March-April - GlobeNewsWire
- 3 months ago - Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat - GlobeNewsWire
- 3 months ago - ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting - GlobeNewsWire
- 3 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024 - GlobeNewsWire
- 4 months ago - ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences - GlobeNewsWire
- 4 months ago - ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting - GlobeNewsWire